GPX4 and neoplasm: Moreover, the expressions of CASP6, GPX4, GSDMC, and NOD2 could increase the susceptibility of tumor cells to paclitaxel, 5-fluorouracil, dasatinib, and gefitinib (Figures 7A–D).